{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:14:43Z","timestamp":1787163283560,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.reth.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T16:42:13Z","timestamp":1685637733000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-9356","authenticated-orcid":false,"given":"Tsutomu","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-838X","authenticated-orcid":false,"given":"Ryosuke","family":"Maeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-3978","authenticated-orcid":false,"given":"Shuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-1332","authenticated-orcid":false,"given":"Young-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ijc.2910160205","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells","volume":"16","author":"Herberman","year":"1975","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"\"Natural\" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jnci\/59.1.77","article-title":"Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line","volume":"59","author":"Ortaldo","year":"1977","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6055","key":"10.1016\/j.reth.2023.05.006_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.reth.2023.05.006_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the 'missing self': MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"issue":"6307","key":"10.1016\/j.reth.2023.05.006_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/349329a0","article-title":"Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice","volume":"349","author":"Bix","year":"1991","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.reth.2023.05.006_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00281-018-0685-x","article-title":"Activating and inhibitory receptors expressed on innate lymphoid cells","volume":"40","author":"Guia","year":"2018","journal-title":"Semin Immunopathol"},{"issue":"19","key":"10.1016\/j.reth.2023.05.006_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194896","article-title":"Evaluation of comprehensive gene expression and NK cell-mediated killing in glioblastoma cell line-derived spheroids","volume":"13","author":"Morimoto","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.reth.2023.05.006_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2012.01.001","article-title":"NK cell MHC class I specific receptors (KIR): from biology to clinical intervention","volume":"24","author":"Thielens","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bbrc.2019.11.099","article-title":"MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3","volume":"523","author":"Zhou","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.reth.2023.05.006_bib13","first-page":"546","article-title":"Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma","volume":"9","author":"Hercend","year":"1990","journal-title":"J\u00a0Biol Response Modif"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib14","first-page":"34","article-title":"Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in\u00a0vivo natural killer cell activity","volume":"3","author":"Miller","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.reth.2023.05.006_bib16","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reth.2023.05.006_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"11","key":"10.1016\/j.reth.2023.05.006_bib18","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/1078-0432.CCR-03-0683","article-title":"Treatment of colon and lung cancer patients with ex\u00a0vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial","volume":"10","author":"Krause","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.20892\/j.issn.2095-3941.2019.0187","article-title":"Technical advances in NK cell-based cellular immunotherapy","volume":"16","author":"Fang","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.reth.2023.05.006_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.reth.2023.05.006_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"10.1016\/j.reth.2023.05.006_bib25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"5 Pt 1","key":"10.1016\/j.reth.2023.05.006_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1203\/01.PDR.0000156501.55431.20","article-title":"Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections","volume":"57","author":"Dalle","year":"2005","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.reth.2023.05.006_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.reth.2023.05.006_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212455","article-title":"Ex\u00a0vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in\u00a0vitro","volume":"14","author":"Tanaka","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.reth.2023.05.006_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","article-title":"Establishment of an efficient ex\u00a0vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors","volume":"21","author":"Nakazawa","year":"2022","journal-title":"Regen Ther"},{"issue":"7","key":"10.1016\/j.reth.2023.05.006_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073489","article-title":"CRISPR-Cas9-Mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells","volume":"22","author":"Morimoto","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.reth.2023.05.006_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189975","article-title":"Ex\u00a0vivo expanded and activated natural killer cells prolong the overall survival of mice with glioblastoma-like cell-derived tumors","volume":"22","author":"Shida","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040998","article-title":"Effect of CRISPR\/Cas9-Mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in\u00a0vitro human glioblastoma cell growth","volume":"9","author":"Nakazawa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.reth.2023.05.006_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/srep45839","article-title":"Entire CD3epsilon, delta, and gamma humanized mouse to evaluate human CD3-mediated therapeutics","volume":"7","author":"Ueda","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12015-022-10449-2","article-title":"The role of NK cells and their exosomes in graft versus host disease and graft versus leukemia","volume":"19","author":"Zafarani","year":"2023","journal-title":"Stem Cell Rev Rep"},{"issue":"5","key":"10.1016\/j.reth.2023.05.006_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.reth.2023.05.006_bib36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bbmt.2016.12.638","article-title":"Donor killer immunoglobulin-like receptor haplotype B\/x induces severe acute graft-versus-host disease in the presence of human leukocyte antigen mismatch in T cell-replete hematopoietic cell transplantation","volume":"23","author":"Hosokai","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.173.1.25","article-title":"Differentiation of T cell lymphokine gene expression: the in\u00a0vitro acquisition of T cell memory","volume":"173","author":"Ehlers","year":"1991","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.13464","article-title":"NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion-the differences and similarities","volume":"166","author":"Roe","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.reth.2023.05.006_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734551","article-title":"NK cells in a tug-of-war with cancer: the roles of transcription factors and cytoskeleton","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.reth.2023.05.006_bib40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/2326-6066.CIR-21-0110","article-title":"Mitochondria as playmakers of CAR T-cell fate and longevity","volume":"9","author":"Rostamian","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.reth.2023.05.006_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.reth.2023.05.006_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12896-019-0564-0","article-title":"A\u00a0simple method for in\u00a0vitro preparation of natural killer cells from cord blood","volume":"19","author":"Mu","year":"2019","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.reth.2023.05.006_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent Innovations and future developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.reth.2023.05.006_bib47","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/1078155220967087","article-title":"Temozolomide-induced aplastic anaemia: case report and review of the literature","volume":"27","author":"Gilbar","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.reth.2023.05.006_bib48","first-page":"440","article-title":"Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis","volume":"268","author":"Petrelli","year":"2021","journal-title":"J\u00a0Neurol"},{"issue":"357","key":"10.1016\/j.reth.2023.05.006_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.reth.2023.05.006_bib50","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.reth.2023.05.006_bib51","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.reth.2023.05.006_bib52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.reth.2023.05.006_bib53","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.2147\/OTT.S139986","article-title":"Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer","volume":"10","author":"Liang","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"6","key":"10.1016\/j.reth.2023.05.006_bib54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.reth.2023.05.006_bib55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320423000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320423000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:42:39Z","timestamp":1762450959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320423000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S2352320423000445"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2023.05.006","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}